All In Biotech

Drug Trial Radar · NCT01299116

Long-Acting Reversible Contraception

Long-Acting Reversible Contraception: New Research to Reduce Unintended Pregnancy

Last checked: Nov 19, 2026Latest source record: Feb 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 916 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

916

Actual

Start

Dec 2011

Primary completion

Jun 2016

Study completion Dec 2016

Sponsor

Lead sponsor
FHI 360Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 29 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In the proposed study, women aged 18-29 seeking oral or injectable contraception will be offered an opportunity to try LARC instead; the FDA-approved options include two types of intrauterine products and one type of subdermal contraceptive implant. Over a 24 month period, the experiences of LARC users will be compared to the experiences of those opting for their initial short-acting method.

Conditions

  • Contraception

Interventions

  • DMPADrug

    Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.

  • oral contraceptivesDrug

    Oral contraceptives (any variety of formulations are permitted)

  • Implanon®Drug

    Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)

  • ParaGard®Drug

    Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)

  • Mirena®Drug

    Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contraceptive Method DiscontinuationTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Planned Parenthood Central North Carolina

    Chapel Hill, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.